Trials / Approved For Marketing

Approved For MarketingNCT04914247

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Status: Approved For Marketing
Phase: —
Study type: Expanded Access
Enrollment: —

Sponsor: Actelion · Industry
Sex: —
Age: —
Healthy volunteers: —

Summary

The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.

Conditions

Non-healing Wound
Thromboangiitis Obliterans

Interventions

Type	Name	Description
DRUG	Selexipag

Timeline

First posted: 2021-06-04
Last updated: 2026-03-27

Source: ClinicalTrials.gov record NCT04914247. Inclusion in this directory is not an endorsement.